Cohort study of infectious disease risk management in Rheumatoid Arthritis patients receiving tocilizumab

Cohort study of infectious disease risk management in Rheumatoid Arthritis patients receiving tocilizumab - Cohort study of infectious disease risk management in Rheumatoid Arthritis patients receiving tocilizumab (ACT4U-study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008889

Enrollment

Registered

2012-09-10

Start date

2009-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patients who fulfilled the American College R classification criteria. 2)RA patients administered tocilizumab for the first time between April 2009 and March 2011.

Exclusion criteria

Exclusion criteria: Patients who had functional class4 Using Steinbrocker criteria

Design outcomes

Primary

Measure	Time frame
Occurrence frequency of severe infection in RA patients with tocilizumab under the infectious disease risk management.	—

Secondary

Measure	Time frame
Hospitalization for infectious disease and its duration.the reduction dose of disease-modifying antirheumatic drugs. Clinical composite activity indices at 24 and 48weeks (DAS28, CDAI, Boolean index). Persistence rate of tocilizumab at 48weeks	—

Countries

Japan

Outcome results